Re: Phase III, randomized, double-blind, multicenter trial comparing orteronel (TAK-700) plus prednisone with placebo plus prednisone in patients with metastatic castration-resistant prostate cancer that has progressed during or after docetaxel-based therapy: ELM-PC 5

Samir S. Taneja

Research output: Contribution to journalComment/debatepeer-review

Original languageEnglish (US)
Number of pages1
JournalJournal of Urology
Volume194
Issue number4
DOIs
StatePublished - Oct 1 2015

ASJC Scopus subject areas

  • Urology

Cite this